ELN-DAVID is the international working group for MRD ASSESSMENT and VALIDATION in AML and is part of the European LeukemiaNet (ELN).
The objective of ELN-DAVID is to promote measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) and related diseases through:
All diagnostic laboratory MRD techniques are subject to evaluation and standardization by ELN-DAVID including, but not limited to quantitative polymerase chain reaction (qPCR), multicolor flow cytometry (MFC), next-generation sequencing (NGS) and digital PCR (dPCR).
Executive Board
Michael Heuser
Chair
Jacqueline Cloos
Vice-Chair
Christian Thiede
Treasurer
Subcommittees
Sylvie Freeman
Flow-MRD
Francesco Buccisano
Flow-MRD
Christian Thiede
qPCR-MRD
Richard Dillon
qPCR-MRD
Peter Valk
NGS-MRD
Christopher Hourigan
NGS-MRD
Konstanze Döhner
Clinical Aspects of MRD
Gail Roboz
Clinical Aspects of MRD
Advisory board
Gert Ossenkoppele
Marion Subklewe
Adriano Venditti
Roland Walter
Brent Wood
Structure and Management
ELN-DAVID is governed by the executive board. The executive board consists of the chair, the vice-chair, the treasurer and subcommittee chairs for flow-, qPCR- and NGS-MRD, and the clinical subcommittee.
All members are approved by the executive board. The advisory board members and patient representatives are appointed by the executive board. Members, advisory board and patient representatives participate in the general assembly and elect the executive board members. The period of office of the members of the Board is three years.
The executive board may appoint administrative directors who legally represent ELN-DAVID in the participating countries.
Admission and Membership
- New members may apply for admission to ELN-DAVID in writing or orally to the chair of ELN-DAVID .
- The application should be supported by a letter of recommendation from a full member of ELN-DAVID and/or by proof of a publication on MRD in AML as first or last author.
- The executive board of ELN-DAVID decides on the admission of new members.